US equities
|
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
NVDA
$125.53
▼-14.01%
ANT
$88.91
▼-8.50%
MU
$594.51
▼-13.89%
AMD
$424.39
▼-13.25%
AAPL
$342.56
▼-1.90%
MSFT
$484.52
▼-2.77%
AMZN
$246.82
▼-4.10%
AVGO
$304.41
▼-12.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Latest News about XNAS:OKYO
Recent news which mentions XNAS:OKYO
Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
June 01, 2023
Tickers
ALPMF
ISEE
OKYO
VTRS
Tags
XNAS:OKYO
OKYO Pharma
From
TheNewswire.com - RSS (Media)
OKYO Pharma reaches milestone with first patient screening for dry eye disease trial
May 04, 2023
Tags
OKYO Pharma Ltd
XNAS:OKYO
XLON:OKYO
From
TheNewswire.com - RSS (Media)
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
March 28, 2023
Tickers
ALDX
OCUL
OKYO
TARS
Tags
OKYO Pharma
XNAS:OKYO
From
TheNewswire.com - RSS (Media)
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
February 23, 2023
Tickers
ALDX
OKYO
TARS
Tags
XNAS:OKYO
OKYO Pharma
From
TheNewswire.com - RSS (Media)